'The Global Market for Needle-Free Injection Devices Will be Worth $4.49bn by 2022' Predicts visiongain Research

'The Global Market for Needle-Free Injection Devices Will be Worth $4.49bn by 2022' Predicts visiongain Research PR Newswire LONDON, September 14, 2012 LONDON, September 14, 2012 /PRNewswire/ -- A new report by visiongain, a London-based business information provider, predicts that the global market for Needle-Free Injection Devices will be worth $4.49bn by 2022. The market generated sales of $1.09bn in 2011. The delivery of medicine and drugs to patients is typically though the use of pills, tablets or even in liquid form. In some cases when the drug needs to reach the systemic circulation quicker, or when the drug has a shorter half life, often seen during emergencies, the drug will be administered by injection, for example, intravenously (i.v.). Indeed, there are large numbers of therapies, particularly protein-, gene- and vaccine-based medications that cannot be delivered orally. In recent years however, there has been growing concern over the use of needle-based injections. Much of this concern is psychologically-based where patients suffer from a phobia of needles. This has been particularly documented across large demographic groups, such as diabetics. One such alternative, which is growing in popularity and has received considerable attention during the past few years (especially as the safety and efficacy of needle/syringe delivery has been questioned) is Needle-Free Injection (NFI) technology.